Fluorocarbon-based in vivo oxygen transport and delivery systems.
The approval of Fluosol, a fluorocarbon emulsion for oxygenating the myocardium during the transluminal coronary angioplasty procedure, is a landmark in the field of injectable oxygen carriers, the so-called blood substitutes. This review discusses the advances made since this first emulsion was initially developed about 12 years ago. Attention is focused on the progress achieved in the preparation and selection of new, better-defined and faster-excreted fluorocarbons, and better surfactants, improved emulsions, knowledge of structure/property relationships along with an improved understanding of the physiologic response to their administration. These advances have led to the development of a second generation of highly concentrated, fluid and stable injectable oxygen carriers suitable for a broad range of clinical applications. Prospects for further progress and future generations of emulsions are also outlined.
Riess
J G
JG
Laboratoire de Chimie Moléculaire, Associé au CNRS, Université de Nice-Sophia Antipolis, France.
D000818:Animals; D001802:Blood Substitutes; D002245:Carbon Dioxide / Q000097:blood; D004338:Drug Combinations; D004655:Emulsions; D005466:Fluorocarbons / Q000737:chemistry; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D010100:Oxygen / Q000097:blood*; D013501:Surface-Active Agents
D001802:Blood Substitutes; D004338:Drug Combinations; D004655:Emulsions; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; D013501:Surface-Active Agents; D002245:Carbon Dioxide; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; C050455:fluosol; D010100:Oxygen